Boehringer Ingelheim is a Germany-based company with interests in pharmaceuticals, biopharmaceuticals, chemicals and animal health products. The company's main focus is on human health products in its pharmaceutical division and is active across all the major treatment areas including respiratory,

Before the 18th European Congress of Clinical Microbiology and Infectious Disease (ECCMID) opening here tomorrow, Bruker Daltonics announces that it has received EN ISO 13485 certification for its German operations. This ISO 13485 certification is an important milestone in the

Expected to lead to additional global capacity through targeted acquisitions (PRWeb Apr 18, 2008) Read the full story at http://ww1.prweb.com/releases/2008/04/prweb872364.htm

Critical ISO 11607 clause 6 compliance questions answered in three chapter webinar series. (PRWeb Apr 18, 2008) Read the full story at http://ww1.prweb.com/releases/2008/04/prweb868634.htm

Chembio Diagnostics has signed an exclusive development agreement with Bio-Rad Laboratories, to develop a multiplex test employing Chembio's patented DPP Dual Path Platform test system.

Neurogen has closed a private placement offering of exchangeable preferred stock and warrants with selected institutional investors for gross proceeds of approximately $30.6 million before fees and expenses.

IMS Health has revealed that the emerging markets fueled the growth in global prescription drug sales, reported PharmaTimes.

Walmark, the Czech manufacturer of nutritional supplements and OTC drugs, has set up its first office in western Europe - in Paris, reported PJB news.

DIA, the Drug Information Association, has set up an office in Mumbai, India, reported PJB news.

Ziopharm Oncology has presented positive data from a Phase II study of darinaparsin, the company's novel organic arsenic compound, in advanced hematological malignancies.

Human Genome Sciences has reacquired rights to the Trail receptor antibodies HGS-ETR1 and HGS-ETR2 from GlaxoSmithKline, in return for a reduction in royalties due to Human Genome if Syncria is commercialized.

Biopharmaceutical company BrainCells has initiated a Phase IIa clinical trial with its lead product candidate, BCI-540, for the treatment of depression with anxiety.

Specialty pharmaceutical company Osteologix has completed $5.3 million private placement of common stock and warrants.

Cardiovascular Sciences has negotiated an agreement with Garden State Nutritionals, a division of Vitaquest International.

MethylGene has reported encouraging preclinical data for MGCD265, an oral, multi-targeted kinase inhibitor for cancer that targets the c-Met, Tie-2, Ron and VEGF receptor tyrosine kinases.

Chiltern, a global research organization, has opened a new office in St Petersburg, Russia following the appointment of Alexey Kornilov as general manager of its Russian operations.

Kosan Biosciences has initiated the Phase II trial of epothilone KOS-1584 in patients with non-small cell lung cancer.

US based Paratek Pharmaceuticals has closed the second and final tranche of a $40 million private financing.

Teva Pharmaceutical Industries has said that the FDA has granted tentative approval for the company's abbreviated new drug application to market its generic version of Lilly's osteoporosis treatment Evista tablets, 60mg.

Santarus has announced that its licensor, the University of Missouri, has received a notice of allowance from the US Patent and Trademark Office for US patent application, covering methods for treating acid-caused gastrointestinal disorders by administering a solid pharmaceutical composition